Where will life sciences investment go in 2027? Meet the #1 panel of the 5th Life Science Funding Forum
On December 9, 2026, the CQIB invites you to the Holiday Inn Laval for the 5th edition of the Life Sciences Financing Forum. Once again, the event brings together the people shaping the financing of health innovation in Quebec and across Canada.
A panel to understand where capital is headed
The first panel of the day will tackle a question on every entrepreneur’s mind: where will life sciences investment go in 2027? Four key players in financing will share their vision of upcoming trends, priorities and opportunities.
Meet the panelists
Elisha Krauss, Associate Principal at BDC C, invests in early-stage Canadian companies in the therapeutics and medical devices sectors.
Youssef Bennani, Managing Partner at CTI Life Sciences Fund d, he holds a PhD and an MBA and has pharmaceutical R&D experience, which gives him both a scientific and a financial perspective on projects.
Cedric Bisson, Partner at Teralys Capital , focuses on life sciences and healthcare investments. He holds an M.D. from McGill University and a law degree from Université de Montréal, and previously led the life sciences practice at iNovia Capital and worked at McKinsey & Company. Teralys is Canada’s largest innovation-focused investor.
Ivan Shaw, Principal at TVM Capital Life Science l, supports high-potential life sciences companies. He holds a PhD in neurological sciences from McGill University and has served as CEO of several companies developing therapeutic assets in oncology, immunology and neuroscience through to proof of concept. TVM Capital is dedicated exclusively to life sciences.
Why attend ?
Entrepreneurs, investors and industry professionals: this discussion will give you a better understanding of where capital is heading, and what investors expect from the companies they fund.
It is also a unique opportunity to connect with these experts and build strategic relationships at the heart of the life sciences ecosystem.
Comments